A developer of novel biologic for eye diseases, Opthea Limited (ASX:OPT) disclosed positive topline findings of its Phase 2a trial evaluating efficacy and safety of OPT-302 administered with aflibercept (Eylea®) for treatment of persistent diabetic macula edema (DME).
This trial is a randomized, sham-controlled, double-masked, proof-of-concept clinical study conducted at 53 sites in Australia, the US, Latvia and Israel.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.